A Preview Of Celcuity’s Earnings
Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Monday, 2023-05-15. Here’s what investors need…
Celcuity To Present Updated Results For Treatment-Naïve Patients From Phase 1b Study Of Gedatolisib At The 2023 ESMO Breast Cancer Annual Congress
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting updated results for treatment-naïve
Celcuity Presents Preclinical Data On Therapeutic Effects Of Gedatolisib In Gynecological Cancer Models At AACR Annual Meeting 2023
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million.
Celcuity Announced FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that the U.S.